TORONTO, Dec. 14, 2022 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being is pleased to announce that it has closed the second tranche of its previously announced private placement of up to CAD$3 million. The Company has issued 7,751…

Source

Previous articleBraxia Scientific Reports Q2 2023 Financial Results; Focused on Growing Clinic and Telemedicine Delivery of Novel Mental Health Treatments in North America
Next articleSilo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine